Characteristics of patients included into training and validation cohorts
Parameter . | . | Training cohort (n = 176) . | Validation cohort (n = 486) . | Total . |
---|---|---|---|---|
WHO diagnosis | BL | 16 | 13 | 29 |
CLL | 20 | 125 | 145 | |
DLBCL | 40 | 64 | 104 | |
FL | 20 | 109 | 129 | |
HCL | 20 | 38 | 58 | |
LPL | 20 | 54 | 74 | |
MCL | 20 | 56 | 76 | |
MZL | 20 | 27 | 47 | |
Gender | Female/male | 65/111 | 181/305 | 246/416 |
Age (y) | Median (range) | 67 (2-93) | 65 (3-95) | 66 (2-95) |
WBC (109/L)* | Median (range) | 8.1 (0.31-296) | 10 (0.8-217) | 9.4 (0.31-296) |
% lymphoma cells† | Median (range) | 42.8 (0.12-99) | 41.6 (0.14-99) | 41.8 (0.12-99) |
Disease phase | Diagnosis | 153 | 421 | 574 |
Follow-up | 10 | 24 | 34 | |
Relapse | 13 | 41 | 54 | |
Sample type | PB | 55 | 201 | 256 |
BM | 65 | 163 | 228 | |
LN | 41 | 87 | 128 | |
TM | 8 | 24 | 32 | |
Other | 7 | 11 | 18 |
Parameter . | . | Training cohort (n = 176) . | Validation cohort (n = 486) . | Total . |
---|---|---|---|---|
WHO diagnosis | BL | 16 | 13 | 29 |
CLL | 20 | 125 | 145 | |
DLBCL | 40 | 64 | 104 | |
FL | 20 | 109 | 129 | |
HCL | 20 | 38 | 58 | |
LPL | 20 | 54 | 74 | |
MCL | 20 | 56 | 76 | |
MZL | 20 | 27 | 47 | |
Gender | Female/male | 65/111 | 181/305 | 246/416 |
Age (y) | Median (range) | 67 (2-93) | 65 (3-95) | 66 (2-95) |
WBC (109/L)* | Median (range) | 8.1 (0.31-296) | 10 (0.8-217) | 9.4 (0.31-296) |
% lymphoma cells† | Median (range) | 42.8 (0.12-99) | 41.6 (0.14-99) | 41.8 (0.12-99) |
Disease phase | Diagnosis | 153 | 421 | 574 |
Follow-up | 10 | 24 | 34 | |
Relapse | 13 | 41 | 54 | |
Sample type | PB | 55 | 201 | 256 |
BM | 65 | 163 | 228 | |
LN | 41 | 87 | 128 | |
TM | 8 | 24 | 32 | |
Other | 7 | 11 | 18 |